Life Scientist > Lab Technology

Challenger betting on biotech for super boom

16 October, 2002 by David Binning

Perched at the top of the ABN Amro Building in the heart of Sydney's 'big end' of town, Sean Mordaunt, business development manager with Challenger International's Corporate Superannuation Fund, thrives on the manic energy pulsing through the busy business hub and the harbour below.


Xcell move disappoints stranded WA researchers

15 October, 2002 by Melissa Trudinger

Researchers at the Optical and Biomedical Engineering Laboratory (OBEL) at the University of WA were left surprised and disappointed after a decision by Perth-based company Xcell Diagnostics to withdraw funding from the lab's skin cancer project, which aimed to develop a new optical pen probe technique for early detection of skin cancers.


Bio-IT hot topic at upcoming seminars

15 October, 2002 by Iain Scott

Research firm IDC is to host two breakfast briefings on the bio-IT industry, with a particular focus on Australia and the Asia-Pacific.


South Africans quick to pick up Iatia technology

15 October, 2002 by Melissa Trudinger

Iatia's QPe phase imaging technology proved popular at the recent International Congress on Electron Microscopy in Durban, South Africa, according to CEO Brian Powell.


Pi2 heads for the great outdoors

15 October, 2002 by Iain Scott

Sydney-based company Pi2 Limited has touted a new business strategy with two acquisitions, one in life sciences and the other in outdoor advertising.


AstraZeneca plans for growth in Qld natural products centre

15 October, 2002 by Pete Young

Pharmaceutical company AstraZeneca plans to augment the Queensland-based natural product research centre in which it has invested $55 million since 1993.


Biota braces for showdown with 'corporate rationaliser'

14 October, 2002 by Pete Young

The scene has been set for a possible showdown next month between the board of drug discovery company Biota Holdings and Perth businessman Farooq Khan.


Mattick resigns from Benitec board

09 October, 2002 by Melissa Trudinger

The co-director of Queensland's Institute for Molecular Bioscience>, Prof John Mattick, has resigned from his position on Benitec's board of directors while he is in Germany on a sabbatical.


CSIRO sackings rumours prompt warnings

02 October, 2002 by Pete Young

Reported plans to sack up to 26 staff from CSIRO's Division of Land and Water have touched off warnings about the organisation's long-term health from Federal Opposition and union sources.


Personal flavour to Lemberg Medal win

02 October, 2002 by Iain Scott

The 2002 ASBMB Lemberg Medal has special significance for its recipient, Prof Philip Board of the Australian National University.


More than 1200 new projects funded in latest ARC round

02 October, 2002 by Iain Scott

A total of 1252 new projects are to receive Australian Research Council (ARC) funding, totalling $289.5 million over the next three years, it was announced today.


Better believe it - science isn't natural

30 September, 2002 by Iain Scott

It was, as he admitted himself, an unusual topic with which to kick off a cell biology meeting. But Prof Lewis Wolpert's plenary lecture, 'The Biology of Belief', which he gave at the ComBio 2002 meeting in Sydney this morning, straddled clinical research, anthropology, ancient history and technology -- setting the tone for the breadth of research that was to come at the conference.


Over 1000 in attendance for ComBio kick-off

30 September, 2002 by Iain Scott

More than 1000 delegates have rolled up for this year's ComBio conference at Sydney's Darling Harbour, according to organisers.


Iatia MD Cussinet resigns

26 September, 2002 by Melissa Trudinger

The resignation of Iatia managing director Philippe Cussinet will not impact the growth of the company, according to CEO Brian Powell.


AusBiotech to probe industry's insurance woes

25 September, 2002 by Melissa Trudinger

Rumours that biotechnology companies are finding it hard to renew professional indemnity insurance policies have led industry association AusBiotech to investigate the potential for problems.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd